Introduction
The research peptide landscape in 2026 looks dramatically different from even two years ago. New therapeutic targets, novel molecular architectures, and AI-accelerated drug design are producing peptides that push the boundaries of conventional analytical testing.
At ACS Peptide Testing Labs, we're at the front lines of these changes, adapting our methods and investing in new capabilities as the peptides themselves become more complex. Here's our overview of the most significant emerging peptides and what they mean for the testing industry.
The Next Wave of GLP-1 and Multi-Agonist Peptides
Retatrutide: The Triple Agonist
Retatrutide (LY3437943) is Eli Lilly's triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 3 data has shown weight loss of up to 24%, making it potentially the most effective obesity peptide yet.
Testing implications:
- Retatrutide's complex structure (39 amino acids with a C20 fatty acid moiety) requires specialized HPLC gradient methods
- Identity confirmation needs high-resolution mass spectrometry to distinguish it from structurally similar GLP-1 agonists
- We've developed retatrutide-specific testing protocols to address these challenges
Survodutide: Glucagon/GLP-1 Dual Agonist
Boehringer Ingelheim's survodutide targets both glucagon and GLP-1 receptors, a different dual-agonist approach than tirzepatide's GIP/GLP-1 mechanism. Phase 3 trials for MASH (metabolic-associated steatohepatitis) and obesity are ongoing.
Testing note: Survodutide's glucagon receptor activity means degradation products could have unexpected biological activity, making purity testing especially important.
Oral Peptide Formulations
The industry is investing heavily in oral peptide delivery. Eli Lilly's orforglipron (technically a non-peptide GLP-1 agonist) and Novo Nordisk's oral semaglutide (Rybelsus) are leading this trend, but true oral peptide formulations with permeation enhancers are in development.
Testing challenge: Oral formulations use excipients that can interfere with standard HPLC methods. Labs need to develop extraction protocols that separate the peptide from its delivery matrix before analysis.
Mitochondrial-Targeted Peptides
SS-31 (Elamipretide)
SS-31 continues to gain research interest for its ability to target cardiolipin in the inner mitochondrial membrane. Clinical trials are exploring applications in heart failure, kidney disease, and age-related mitochondrial dysfunction.
Our SS-31 testing guide covers the specific analytical considerations for this small but structurally unique tetrapeptide.
MOTS-c
MOTS-c, a mitochondrial-derived peptide, is being studied for metabolic regulation and exercise mimetic effects. As a naturally occurring peptide encoded by mitochondrial DNA, it represents a new class of signaling molecules.
Testing note: MOTS-c's 16-amino-acid sequence with a methionine-rich region makes it susceptible to oxidation artifacts. Proper sample handling and method development are critical for accurate purity results.
Tissue Repair and Regenerative Peptides
BPC-157 Remains the Volume Leader
BPC-157 (Body Protection Compound) continues to be one of the most-tested peptides at our lab. Research interest spans wound healing, gut protection, tendon repair, and neurological applications.
Testing trend: We're seeing increased demand for stability testing of BPC-157, particularly from suppliers looking to establish shelf-life claims. Our data suggests that storage conditions significantly impact BPC-157 degradation rates.
TB-500 (Thymosin Beta-4)
Thymosin Beta-4 research continues in wound healing and cardiac repair. As a 43-amino-acid peptide, it presents moderate analytical complexity.
GHK-Cu Peptide Complexes
The GHK-Cu tripeptide-copper complex is gaining traction in both cosmetic and regenerative research. Testing copper-containing peptides requires ICP-MS to verify metal content alongside standard purity analysis.
AI-Designed Peptides: The New Frontier
What AI Is Changing
Machine learning platforms are now designing novel peptide sequences optimized for specific receptor binding profiles, stability, and cell permeability. Companies like Generate Biomedicines, Absci, and academic labs are producing peptides that have never existed in nature.
Testing implications for AI-designed peptides:
- No reference standards exist for novel sequences, labs must develop custom methods
- Predicted vs. actual folding can differ, requiring circular dichroism or NMR verification
- Synthesis fidelity becomes critical: is the manufacturer producing exactly what the algorithm designed?
De Novo Antimicrobial Peptides
AI-designed antimicrobial peptides (AMPs) represent a growing testing category. These peptides are engineered for activity against drug-resistant bacteria, and each new sequence requires method development for purity and identity verification.
